Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017186 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

A Phase 2 study of Malignant Mesothelioma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
69
Enrollment target
20
Study locations

NCT00017186: Completed Phase 2 study of Malignant Mesothelioma, sponsored by Alliance for Clinical Trials in Oncology.

NCT00017186 is a Phase 2 study of Malignant Mesothelioma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 69 participants, roughly in line with the 70-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017186, a Phase 2 study of Malignant Mesothelioma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
69 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.

Conditions Studied

Malignant Mesothelioma

Interventions

  • DRUG epirubicin hydrochloride
  • DRUG gemcitabine hydrochloride

Study Locations (20)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • Coborn Cancer Center - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

North Dakota

  • Medcenter One Health System - Bismarck
  • CCOP - Merit Care Hospital - Fargo

Alabama

  • MBCCOP - Gulf Coast - Mobile

Arizona

  • CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Kansas

  • CCOP - Wichita - Wichita

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2001-07
Est. Completion 2008-05
Phase Phase 2
Alliance for Clinical Trials in Oncology

446 total trials

What the finished NCT00017186 record still lists

NCT00017186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, roughly in line with the 70-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target.

The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which epirubicin hydrochloride is the first listed.

NCT00017186 names 20 study sites across 13 states, led by Minnesota, Iowa, Illinois.

Frequently Asked Questions

What is clinical trial NCT00017186 about?

NCT00017186 is a clinical study titled "Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have ma...

What is the current status of trial NCT00017186?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2001-07. Estimated completion is 2008-05.

What conditions does trial NCT00017186 study?

This clinical trial studies the following conditions: Malignant Mesothelioma.

What interventions are being tested in trial NCT00017186?

The interventions under investigation include: epirubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00017186?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00017186 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00017186's enrollment target sits among peer trials

69 3rd of 11 higher than 9 of 11 other Malignant Mesothelioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04020575 · 69 participants · Phase 1

    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

  • NCT04163614 · 69 participants · NA

    Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

  • NCT04164641 · 69 participants · NA

    Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration

  • NCT04493372 · 69 participants · NA

    Deciphering Preserved Autonomic Function After Spinal Cord Injury

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00017186, the US trial registry maintained by the National Library of Medicine. NCT00017186 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.